Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib in advanced solid tumors or CLL
NCT02316197Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of peposertib in solid tumor and chronic lymphocytic leukemia (CLL) (7 arms), sponsored by Merck KGaA. Primary endpoint: Dose Limiting Toxicities. Started Dec 2014; status: completed.
02
Drugs
peposertib
03
Conditions
solid tumorchronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02316197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316197.